A5059690857- Renal cell carcinoma treatment
- Prostate Cancer Treatment and Research
- Cancer Immunotherapy and Biomarkers
- Renal and related cancers
- Cancer Genomics and Diagnostics
- Radiopharmaceutical Chemistry and Applications
- Cancer Treatment and Pharmacology
- Bladder and Urothelial Cancer Treatments
- Cancer, Lipids, and Metabolism
- Prostate Cancer Diagnosis and Treatment
- Ferroptosis and cancer prognosis
- Pancreatic and Hepatic Oncology Research
- Immunotherapy and Immune Responses
- Multiple and Secondary Primary Cancers
- Economic and Financial Impacts of Cancer
- Multiple Myeloma Research and Treatments
- Cancer, Hypoxia, and Metabolism
- Bone health and treatments
- Cancer Diagnosis and Treatment
- Urinary and Genital Oncology Studies
- CAR-T cell therapy research
- Lung Cancer Research Studies
- Advanced Breast Cancer Therapies
- Peptidase Inhibition and Analysis
- PARP inhibition in cancer therapy
Hôpital Européen Georges-Pompidou
2016-2025
Université Paris Cité
2016-2025
Hôpital Européen
2016-2025
Assistance Publique – Hôpitaux de Paris
2016-2025
Paris Cardiovascular Research Center
2015-2025
Inserm
2015-2025
European Hospital
2007-2024
Institut Bergonié
2004-2024
Sorbonne Paris Cité
2012-2024
Dana-Farber Cancer Institute
2007-2024
Since sunitinib malate has shown activity in two uncontrolled studies patients with metastatic renal-cell carcinoma, a comparison of the drug interferon alfa phase 3 trial is warranted.We enrolled 750 previously untreated, carcinoma multicenter, randomized, to receive either repeated 6-week cycles (at dose 50 mg given orally once daily for 4 weeks, followed by 2 weeks without treatment) or 9 MU subcutaneously three times weekly). The primary end point was progression-free survival. Secondary...
Mitoxantrone plus prednisone reduces pain and improves the quality of life in men with advanced, hormone-refractory prostate cancer, but it does not improve survival. We compared such treatment docetaxel this disease.From March 2000 through June 2002, 1006 metastatic cancer received 5 mg twice daily were randomly assigned to receive 12 mitoxantrone per square meter body-surface area every three weeks, 75 or 30 weekly for five six weeks. The primary end point was overall Secondary points...
We conducted a phase 3, randomized, double-blind, placebo-controlled trial of sorafenib, multikinase inhibitor tumor-cell proliferation and angiogenesis, in patients with advanced clear-cell renal-cell carcinoma.From November 2003 to March 2005, we randomly assigned 903 carcinoma that was resistant standard therapy receive either continuous treatment oral sorafenib (at dose 400 mg twice daily) or placebo; 451 received 452 placebo. The primary end point overall survival. A single planned...
A randomized, phase III trial demonstrated superiority of sunitinib over interferon alfa (IFN-alpha) in progression-free survival (primary end point) as first-line treatment for metastatic renal cell carcinoma (RCC). Final analyses and updated results are reported.
Apalutamide, a competitive inhibitor of the androgen receptor, is under development for treatment prostate cancer. We evaluated efficacy apalutamide in men with nonmetastatic castration-resistant cancer who were at high risk metastasis.We conducted double-blind, placebo-controlled, phase 3 trial involving and prostate-specific antigen doubling time 10 months or less. Patients randomly assigned, 2:1 ratio, to receive (240 mg per day) placebo. All patients continued androgen-deprivation...
Abstract BACKGROUND: A phase 3 trial demonstrated superiority at interim analysis for everolimus over placebo in patients with metastatic renal cell carcinoma (mRCC) progressing on vascular endothelial growth factor receptor–tyrosine kinase inhibitors. Final results and of prognostic factors are reported. METHODS: Patients mRCC (N = 416) were randomized (2:1) to 10 mg/d (n 277) or 139) plus best supportive care. Progression‐free survival (PFS) safety assessed the end double‐blind treatment....
Mature survival data and evaluation of vascular endothelial growth factor (VEGF) as a prognostic biomarker from the Treatment Approaches in Renal Cancer Global Evaluation Trial (TARGET) study patients with renal cell carcinoma (RCC) are reported.Nine hundred three previously treated were randomly assigned to receive sorafenib versus placebo. On demonstration progression-free (PFS) benefit sorafenib, placebo offered sorafenib. Overall (OS) was determined at two planned interim analyses one...
Cytoreductive nephrectomy has been the standard of care in metastatic renal-cell carcinoma for 20 years, supported by randomized trials and large, retrospective studies. However, efficacy targeted therapies challenged this standard. We assessed role patients with who were receiving therapies.
Head and neck cancers positive for human papillomavirus (HPV) have a more favorable clinical outcome than HPV-negative cancers, but it is unknown why this the case. We hypothesized that prognosis was affected by intrinsic features of HPV-infected tumor cells or differences in host immune response. In study, we focused on comparison regulatory Foxp3(+) T programmed death-1 (PD-1)(+) microenvironment tumors were negative HPV, two groups matched various biologic parameters. HPV-positive head...
Patients with renal-cell carcinoma who undergo nephrectomy have no options for adjuvant therapy to reduce the risk of recurrence that high levels supporting evidence.
Clear cell renal carcinoma (ccRCC) is characterized by near-universal loss of the short arm chromosome 3, deleting several tumor suppressor genes. We analyzed whole genomes from 95 biopsies across 33 patients with clear carcinoma. find hotspots point mutations in 5′ UTR TERT, targeting a MYC-MAX-MAD1 repressor associated telomere lengthening. The most common structural abnormality generates simultaneous 3p and 5q gain (36% patients), typically through chromothripsis. This event occurs...
Clear cell renal carcinoma (ccRCC) has shown durable responses to checkpoint blockade therapies. However, important gaps persist in the understanding of its immune microenvironment. This study aims investigate expression and prognostic significance checkpoints primary metastatic ccRCC, relation with mature dendritic cells (DC) T-cell densities.We investigated infiltration localization CD8(+) T DC, (PD-1, LAG-3, PD-L1, PD-L2) prognosis, 135 ccRCC tumors 51 lung metastases. RNA data for 496...
The Renal Insufficiency and Cancer Medications (IRMA) study is a French national observational study. results from this of nearly 5,000 patients demonstrated the high prevalence renal impairment in population with solid tumors.Every cancer patient who presented at oncology departments that participated over least 1 2 predefined periods during 2004 were included. function was calculated using Cockcroft-Gault abbreviated Modification Diet Disease (aMDRD) formulae to estimate insufficiency (RI)...
Sunitinib and sorafenib are novel tyrosine kinase inhibitors (TKIs) that have shown significant clinical activity in metastatic clear cell renal carcinoma (RCC). The of sunitinib non-clear histologies has not been evaluated.Clinical features at study entry treatment outcomes were evaluated patients with papillary RCC (PRCC) chromophobe (ChRCC) who received either or as their initial TKI five US French institutions. Response rate survival documented. Fisher's exact test was used for categoric...